
    
      The purpose of this study is to prove that as for disease free survival time, and safety,
      Apatinib with XELOX(Oxaliplatin with Capecitabine) has a better effect over that of XELOX
      adjunct therapy group for postoperative chemotherapy of locally advanced gastric signet ring
      carcinoma with D2 dissection.
    
  